A Phase 2 interventional study of STI571 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-22.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 1 open to participants now, 5 under way, none of them phase 3. imatinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 5th largest by enrollment of the 83 interventional ones that give a count, is one of 3 that started in 1999, is one of 48 in phase 2, and was the 29th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →1 of the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
By country, each count listing its studies:
imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 56 · Phase 3 15 · Phase 4 8
First in 1999; this study’s year is marked. 3 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 532 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 60 across the 83 interventional studies. Of the 72 that completed or were terminated, 20 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 93 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 5th largest by enrollment of the 63 interventional ones that give a count, is one of 3 that started in 1999, is one of 19 in phase 2, and was the 9th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study provided that, in the opinion of the investigator, they had benefited from treatment with STI571 and there were no safety concerns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants included in the study were:
With a documented failure of interferon-alpha (IFN) or an IFN-containing therapy, characterized as resistance or refractoriness defined as any of the following:
In this report all populations were referred to as "relapsed" populations.
Exclusion Criteria:
Participants excluded from the study were:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received STI571, capsules or tablets, orally, once a day at a dose of 400 mg. During the Core Phase of the study, participants received STI571 daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study, and they continued STI571 for as long as the therapy was beneficial or until death, intolerable toxicity or the decision to discontinue by the investigator, whichever came first. (Maximum duration on study was approximately 14 years).
Drug: STI571
STI571 oral capsules or tablets.
Also known as: Imatinib Mesylate
Percentage of Participants With Cytogenetic Response (Complete Cytogenetic Response and Major Cytogenetic Response) to STI571
Response was evaluated from bone marrow aspirates and biopsy samples. Bone marrow cytogenetic studies were performed every 3 months during the core phase of the study, then twice yearly, then annually to evaluate Philadelphia chromosome positive (Ph+). Cytogenetic response was defined as the best response the participant achieved during study. Based on the percentage of Ph+ cells = (positive cells/ examined cells) x100, at each BM assessment the cytogenetic response was classified as: Complete Cytogenetic Response (CCyR):, 0% Ph+ cells; Partial Cytogenetic Response (PCyR):, \>0 - 35% Ph+ cells; Minor: \>35 - 65% Ph+ cells; and Minimal: \>65 - 95% Ph+ cells, None: \>95 % Ph+ cells and Not done: \<20 metaphases were examined and/or response could not be assigned. Major Cytogenetic Response (MCyR) was defined as sum of the CCyR plus PCyR rates.
Time frame: Up to 6 years after the start of treatment
Percentage of Participants With Complete Hematologic Response to STI571
Hematologic response was evaluated from hematology measurements in the peripheral blood. Complete hematological response was defined as normalization of peripheral blood counts \[WBC and platelet count \< upper limit of normal (ULN) at the laboratory where the analysis was performed\], with a normal WBC differential, and no immature granulocytes present, lasting for 4 weeks.
Time frame: 12 months after the start of treatment
Duration of Complete Hematologic Response to STI571
Duration of hematologic response was defined as the time from the first documentation of the complete hematologic response to the date the loss of complete hematologic response is documented. Loss of complete hematological response was defined as a rising WBC count (increased to a level above the ULN at the laboratory where the analysis was performed confirmed by two samples obtained one month apart). The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. Complete hematological response was defined as normalization of peripheral blood counts (WBC and platelet count \< ULN at the laboratory where the analysis was performed), with a normal WBC differential, and no immature granulocytes present, lasting for 4 weeks.
Time frame: 12 months after the start of treatment
Time to Complete Hematologic Response to STI571
Time to Complete Hematologic Response was defined for all participants with calculated confirmed complete hematologic response as the time until first documented response (which was confirmed \>= 4 weeks). Complete hematological response was defined as normalization of peripheral blood counts (WBC and platelet count \< ULN at the laboratory where the analysis was performed), with a normal WBC differential, and no immature granulocytes present, lasting for 4 weeks.
Time frame: 12 months after the start of treatment
Number of Participants With Common Toxicity Criteria Grade 3 or 4 Cancer-related Symptoms
National Cancer Institute (NCI)/ National Institute of Health (NIH) provides a grading (severity) scale for each adverse event (AE) term, the Common Toxicity Criteria (CTC). Grade 3 refers to severe AE and Grade 4 refers to life-threatening or disabling AE. Cancer-related symptoms included fever, night sweats, bone pain, arthralgia, abdominal discomfort, fatigue and anorexia.
Time frame: Up to 9 months after the start of treatment
Number of Participants With Grade 3 or 4 Eastern Cooperative Oncology Group (ECOG) Performance Status
The ECOG performance status was recorded at baseline and every 3 months during the core study. The ECOG Performance Scale has 5 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair.
Time frame: Up to 9 months after the start of treatment
Percentage of Participants Alive Over Time Based on Kaplan-Meier Estimates
Overall survival was defined as the time from the first dose of STI571 to the death of the participant. If a participant is not known to have died, survival was censored at the time of last contact. Kaplan-Meier estimates of the percentage of participants at each time point was calculated.
Time frame: 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 and 156 months
| Milestone | Hematologic Failure | Cytogenetic Failure | Interferon-alpha Intolerance |
|---|---|---|---|
| Started | 152 | 188 | 192 |
| Completed | 12 | 47 | 22 |
| Not completed | 140 | 141 | 170 |
| Withdrew: Adverse event (non-fatal) | 6 | 5 | 19 |
| Withdrew: Abnormal laboratory value (s) | 4 | 2 | 3 |
| Withdrew: Abnormal procedure | 1 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 57 | 43 | 52 |
| Withdrew: No longer requires study drug (bone marrow transplant) | 2 | 4 | 2 |
| Withdrew: Protocol violation | 2 | 2 | 3 |
| Withdrew: Participant withdrew consent | 12 | 21 | 15 |
| Withdrew: Lost to follow-up | 5 | 2 | 3 |
| Withdrew: Administrative problems | 4 | 7 | 6 |
| Withdrew: Adverse event (serious fatal) | 6 | 8 | 9 |
| Withdrew: Not specified (no data collected after cut-off) | 41 | 47 | 58 |
Response was evaluated from bone marrow aspirates and biopsy samples. Bone marrow cytogenetic studies were performed every 3 months during the core phase of the study, then twice yearly, then annually to evaluate Philadelphia chromosome positive (Ph+). Cytogenetic response was defined as the best response the participant achieved during study. Based on the percentage of Ph+ cells = (positive cells/ examined cells) x100, at each BM assessment the cytogenetic response was classified as: Complete Cytogenetic Response (CCyR):, 0% Ph+ cells; Partial Cytogenetic Response (PCyR):, \>0 - 35% Ph+ cells; Minor: \>35 - 65% Ph+ cells; and Minimal: \>65 - 95% Ph+ cells, None: \>95 % Ph+ cells and Not done: \<20 metaphases were examined and/or response could not be assigned. Major Cytogenetic Response (MCyR) was defined as sum of the CCyR plus PCyR rates.
| percentage of participants | Hematologic Failure | Cytogenetic Failure | Interferon-alpha Intolerance |
|---|---|---|---|
| Complete Cytogenetic Response | 29.6 (22.5 to 37.5) | 37.2 (30.3 to 44.6) | 45.8 (38.6 to 53.2) |
| Major Cytogenetic Response | 45.4 (37.3 to 53.7) | 63.8 (56.5 to 70.7) | 65.6 (58.4 to 72.3) |
Hematologic response was evaluated from hematology measurements in the peripheral blood. Complete hematological response was defined as normalization of peripheral blood counts \[WBC and platelet count \< upper limit of normal (ULN) at the laboratory where the analysis was performed\], with a normal WBC differential, and no immature granulocytes present, lasting for 4 weeks.
| percentage of participants | Hematologic Failure | Cytogenetic Failure | Interferon-alpha Intolerance |
|---|---|---|---|
| Percentage of Participants With Complete Hematologic Response to STI571 | 94.1 (89.1 to 97.3) | 97.9 (94.6 to 99.4) | 91.7 (86.8 to 95.2) |
Duration of hematologic response was defined as the time from the first documentation of the complete hematologic response to the date the loss of complete hematologic response is documented. Loss of complete hematological response was defined as a rising WBC count (increased to a level above the ULN at the laboratory where the analysis was performed confirmed by two samples obtained one month apart). The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. Complete hematological response was defined as normalization of peripheral blood counts (WBC and platelet count \< ULN at the laboratory where the analysis was performed), with a normal WBC differential, and no immature granulocytes present, lasting for 4 weeks.
| months | Hematologic Failure | Cytogenetic Failure | Interferon-alpha Intolerance |
|---|---|---|---|
| Duration of Complete Hematologic Response to STI571 | 19.3672 ± 0.6383 | 23.9389 ± 0.506 | 24.6818 ± 0.6507 |
Time to Complete Hematologic Response was defined for all participants with calculated confirmed complete hematologic response as the time until first documented response (which was confirmed \>= 4 weeks). Complete hematological response was defined as normalization of peripheral blood counts (WBC and platelet count \< ULN at the laboratory where the analysis was performed), with a normal WBC differential, and no immature granulocytes present, lasting for 4 weeks.
| months | Hematologic Failure | Cytogenetic Failure | Interferon-alpha Intolerance |
|---|---|---|---|
| Time to Complete Hematologic Response to STI571 | 1.64 (0.6 to 2.8) | 0.72 (0.3 to 2.8) | 0.72 (0.3 to 2.8) |
National Cancer Institute (NCI)/ National Institute of Health (NIH) provides a grading (severity) scale for each adverse event (AE) term, the Common Toxicity Criteria (CTC). Grade 3 refers to severe AE and Grade 4 refers to life-threatening or disabling AE. Cancer-related symptoms included fever, night sweats, bone pain, arthralgia, abdominal discomfort, fatigue and anorexia.
| Participants | Hematologic Failure | Cytogenetic Failure | Interferon-alpha Intolerance |
|---|---|---|---|
| Abdominal Discomfort Grade 3 | 0 | 0 | 0 |
| Abdominal Discomfort Grade 4 | 0 | 0 | 0 |
| Anorexia Grade 3 | 0 | 0 | 0 |
| Anorexia Grade 4 | 0 | 0 | 0 |
| Arthralgia Grade 3 | 0 | 0 | 1 |
| Arthralgia Grade 4 | 0 | 0 | 0 |
| Bone Pain Grade 3 | 0 | 1 | 0 |
| Bone Pain Grade 4 | 0 | 0 | 0 |
| Fatigue Grade 3 | 1 | 0 | 0 |
| Fatigue Grade 4 | 0 | 0 | 0 |
| Fever Grade 3 | 0 | 0 | 0 |
| Fever Grade 4 | 0 | 0 | 0 |
| Night Sweats Grade 3 | 0 | 0 | 0 |
| Night Sweats Grade 4 | 0 | 0 | 0 |
The ECOG performance status was recorded at baseline and every 3 months during the core study. The ECOG Performance Scale has 5 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair.
| Participants | Hematologic Failure | Cytogenetic Failure | Interferon-alpha Intolerance |
|---|---|---|---|
| Grade 3 | 1 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 |
Overall survival was defined as the time from the first dose of STI571 to the death of the participant. If a participant is not known to have died, survival was censored at the time of last contact. Kaplan-Meier estimates of the percentage of participants at each time point was calculated.
| percentage of participants | Hematologic Failure | Cytogenetic Failure | Interferon-alpha Intolerance |
|---|---|---|---|
| 12 Months | 94.7 (89.8 to 97.3) | 98.9 (95.8 to 99.7) | 97.4 (93.9 to 98.9) |
| 24 Months | 88.1 (81.8 to 92.3) | 93.6 (89 to 96.3) | 89.5 (84.3 to 93.1) |
| 36 Months | 84 (77.1 to 89) | 91.5 (86.5 to 94.7) | 83.8 (77.7 to 88.3) |
| 48 Months | 78.4 (70.9 to 84.2) | 87.1 (81.4 to 91.2) | 76.3 (69.6 to 81.7) |
| 60 Months | 73.3 (65.2 to 79.7) | 83.8 (77.6 to 88.4) | 73.6 (66.7 to 79.3) |
| 72 Months | 70.1 (61.9 to 76.9) | 79.7 (73.1 to 84.9) | 71.4 (64.3 to 77.3) |
| 84 Months | 68.5 (60 to 75.5) | 79.7 (73.1 to 84.9) | 67.2 (59.9 to 73.5) |
| 96 Months | 66.5 (57.9 to 73.8) | 79.1 (72.3 to 84.3) | 65.9 (58.6 to 72.3) |
| 108 Months | 63.3 (54.3 to 71) | 78.4 (71.6 to 83.7) | 65.3 (57.9 to 71.7) |
| 120 Months | 61 (51.8 to 69) | 77 (70 to 82.5) | 63.8 (56.3 to 70.4) |
| 132 Months | 59.7 (50.4 to 67.9) | 75.4 (68.2 to 81.2) | 62.3 (54.6 to 69) |
| 144 Months | 57 (47.2 to 65.5) | 73.8 (66.4 to 79.8) | 60.8 (53 to 67.6) |
| 156 Months | 55.5 (45.6 to 64.3) | 70.1 (62.1 to 76.7) | 60.8 (53 to 67.6) |
Collected over Up to approximately 14 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants With Chronic Myeloid Leukemia | — | 13/532 (2.4%) | — |
| Event | All Participants With Chronic Myeloid Leukemia |
|---|---|
| Hip fractureInjury, poisoning and procedural complications | 1/532 |
| FallInjury, poisoning and procedural complications | 1/532 |
| Head injuryInjury, poisoning and procedural complications | 1/532 |
| SarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/532 |
| Prostate AdenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/532 |
| Atrial fibrillationCardiac disorders | 1/532 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/532 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 1/532 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/532 |
| Generalised oedemaGeneral disorders | 1/532 |
Intent-to-treat (ITT) population included all enrolled participants.
| Age, Continuous(years) | Hematologic Failure | Cytogenetic Failure | Interferon-alpha Intolerance | Total |
|---|---|---|---|---|
| Median | 55.5 (18 to 79) | 53.0 (23 to 77) | 59.0 (20 to 90) | 57.0 (18 to 90) |
| Age, Customized(Participants) | Hematologic Failure | Cytogenetic Failure | Interferon-alpha Intolerance | Total |
|---|---|---|---|---|
| Less than (<) 50 years | 57 | 64 | 47 | 168 |
| >= 50 to <= 60 years | 38 | 65 | 50 | 153 |
| >= 60 to <= 70 years | 47 | 44 | 68 | 159 |
| >= 70 years | 10 | 15 | 27 | 52 |
| Sex: Female, Male(Participants) | Hematologic Failure | Cytogenetic Failure | Interferon-alpha Intolerance | Total |
|---|---|---|---|---|
| Female | 50 | 77 | 94 | 221 |
| Male | 102 | 111 | 98 | 311 |
Ran from Dec 1999 to primary completion in Nov 2013, 167 months.
Results were first posted in Jul 2021, 7 years 7 months after primary completion.
Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 167 months is above that.
Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →